肥胖低通气综合征持续气道正压通气的超声心动图变化:长期Pickwick随机对照临床试验
该研究为Pickwick项目(N=221例肥胖低通气综合征合并重度阻塞性睡眠呼吸暂停患者)的预设次要分析,比较3年无创通气与持续气道正压通气对超声心动图结构和功能变化的影响。共196例纳入分析(持续气道正压通气组102例,无创通气组94例)。两组收缩期肺动脉压均随治疗下降(持续气道正压通气组从基线40.5±1.47 mm Hg降至3年时35.3±1.33 mm Hg,无创通气组从41.5±1.56 mm Hg降至35.5±1.42 mm Hg,两组组内纵向变化均P<0.0001),但组间无显著差异。两种治疗同样改善左室舒张功能障碍、缩小左房内径,并改善呼吸功能与呼吸困难。
要点
- 合并重度阻塞性睡眠呼吸暂停的肥胖低通气综合征患者,持续气道正压通气组收缩期肺动脉压从基线40.5±1.47 mm Hg降至3年时35.3±1.33 mm Hg(组内P<0.0001)。
- 无创通气组收缩期肺动脉压从41.5±1.56 mm Hg降至3年时35.5±1.42 mm Hg(组内P<0.0001),与持续气道正压通气组相比组间无显著差异。
- 无创通气与持续气道正压通气同样改善左室舒张功能障碍并缩小左房内径。
- 两种治疗均改善呼吸功能与呼吸困难。
- 共196例纳入分析:持续气道正压通气组102例,无创通气组94例。
适用人群与场景
- 肥胖低通气综合征合并重度阻塞性睡眠呼吸暂停患者(Pickwick项目,N=221例)。
- 预设次要分析共196例纳入分析:持续气道正压通气组102例,无创通气组94例。
处置流程与药物剂量
- 持续气道正压通气治疗3年。
- 无创通气治疗3年。
- 基线与随后连续3年每年行经胸二维及多普勒超声心动图检查,各中心超声心动图医师对治疗分组设盲。
研究设计与关键结果
- 研究类型:大型多中心随机对照试验(Pickwick项目,N=221例肥胖低通气综合征合并重度阻塞性睡眠呼吸暂停患者)的预设次要分析,比较3年无创通气与持续气道正压通气对超声心动图结构和功能变化的影响。
- 共196例纳入分析:持续气道正压通气组102例,无创通气组94例。
- 收缩期肺动脉压:持续气道正压通气组从基线40.5±1.47 mm Hg降至3年时35.3±1.33 mm Hg,无创通气组从41.5±1.56 mm Hg降至35.5±1.42 mm Hg,两组组内纵向变化均P<0.0001,组间无显著差异。
- 无创通气与持续气道正压通气同样改善左室舒张功能障碍并缩小左房内径。
- 两种治疗均改善呼吸功能与呼吸困难。
- 统计方法:线性混合效应模型,纳入治疗组与重复测量交互项以判定持续气道正压通气与无创通气之间的差异效应。
证据类型、等级与局限
- 证据类型:多中心随机对照临床试验的预设次要分析。
- 临床试验注册号:NCT01405976。
- 局限:原文未报告局限性
对床旁实践的改变
- 在合并重度阻塞性睡眠呼吸暂停的肥胖低通气综合征患者中,长期无创通气与持续气道正压通气对肺动脉高压和左室舒张功能障碍的改善程度相似。
- 两种治疗均改善呼吸功能与呼吸困难。
指南或共识出处
- Pickwick项目随机对照临床试验(ClinicalTrials.gov注册号NCT01405976)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Obesity hypoventilation syndrome (OHS) has been associated with cardiac dysfunction. However, randomized trials assessing the impact of long-term noninvasive ventilation (NIV) or continuous positive airway pressure (CPAP) on cardiac structure and function assessed by echocardiography are lacking.Objectives: In a prespecified secondary analysis of the largest multicenter randomized controlled trial of OHS (Pickwick Project; N = 221 patients with OHS and coexistent severe obstructive sleep apnea), we compared the effectiveness of three years of NIV and CPAP on structural and functional echocardiographic changes.Methods: At baseline and annually during three sequential years, patients underwent transthoracic two-dimensional and Doppler echocardiography. Echocardiographers at each site were blinded to the treatment allocation. Statistical analysis was performed using a linear mixed-effects model with a treatment group and repeated measures interaction to determine the differential effect between CPAP and NIV.Measurements and Main Results: A total of 196 patients were analyzed: 102 were treated with CPAP and 94 were treated with NIV. Systolic pulmonary artery pressure decreased from 40.5 ± 1.47 mm Hg at baseline to 35.3 ± 1.33 mm Hg at three years with CPAP, and from 41.5 ± 1.56 mm Hg to 35.5 ± 1.42 with NIV (P < 0.0001 for longitudinal intragroup changes for both treatment arms). However, there were no significant differences between groups. NIV and CPAP therapies similarly improved left ventricular diastolic dysfunction and reduced left atrial diameter. Both NIV and CPAP improved respiratory function and dyspnea.Conclusions: In patients with OHS who have concomitant severe obstructive sleep apnea, long-term treatment with NIV and CPAP led to similar degrees of improvement in pulmonary hypertension and left ventricular diastolic dysfunction.Clinical trial registered with www.clinicaltrials.gov (NCT01405976).
参考来源
- Masa JF, Mokhlesi B, Benítez I, et al. Echocardiographic Changes with Positive Airway Pressure Therapy in Obesity Hypoventilation Syndrome. Long-Term Pickwick Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2020. PMID: 31682462. doi:10.1164/rccm.201906-1122OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。